UNICREDIT BANK/PUT/BIOGEN IDEC/200/0.1/18.12.24 | Real-time BOERSE MUENCHEN 20:40:04 20/06/2024 BST | ||
| 0.91 EUR | -4.21% |
|
| Current month | -4.04% | ||
| 1 month | +2.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 0.91 | -4.21% |
| 19/06/24 | 0.95 | 0.00% |
| 18/06/24 | 0.95 | +7.95% |
| 17/06/24 | 0.88 | +3.53% |
| 14/06/24 | 0.85 | 0.00% |
Real-time BOERSE MUENCHEN
Last update June 20, 2024 at 08:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD0NWR |
| ISIN | DE000HD0NWR8 |
| Date issued | 13/11/2023 |
| Strike | 200 $ |
| Maturity | 18/12/2024 (181 Days) |
| Parity | 10 : 1 |
| Emission price | 1.71 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.35 € |
|---|---|
| Lowest since issue | 0.78 € |
| Spread | 0.02 € |
| Spread % | 2.20% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
223.6
USD
Average target price
284.6
USD
Spread / Average Target
+27.27%
- Stock Market
- Warrants
- Warrant
